Table 1.

Summary of research on TIM3 in COVID-19 patients' samples.

Sample	Increased expression	Groupsa	Ref.
PBMCs	1. CD8+ and CD4+ T cells	1. Severe	1 [33].
	2. NK, CD4+ and CD8+ T cells	2. Patients > Healthy	2 [34].
	3. CD4+ T cells	3. Critical and severe > Healthy	3 [35].
	4. CD8+ T cells	4. Critical > Non-critical & Healthy	4 [36].
	5. CD3+, CD4+ and CD8+ T cells	5. Case report	5 [37].
	6. NKT cells	6. Advanced > Recovered > Healthy	6 [38].
	7. CD4+ T cells	7. Severe > Mild & Asymptomatic	7 [39].
	8. CD4+ and CD8+ T cells	8. Extremely severe	8 [40].
	9. None	9. None	9 [41].
	10. CD4+ and CD8+ T cells	10. Post-acute > Asymptomatic	10 [42].
	11. IFN-γ+ SARS-CoV-2–specific CD4+ T	11. Recovered	11 [43].
	12. CD8+ T cells	12. Co-infected > Mono-infection	12 [36].
	13. CD8+ T subsets and total and central memory CD4+ T subsets	13. Infected mothers	13 [44].
Tissue	1. Lung autopsy	1. COVID-19 > non-COVID-19	1 [45].
	2. Skin biopsy	2. COVID-19 > non- COVID-19	2 [46].
Serum/Plasma	1. Post-acute COVID syndrome serum	1. Post-acute > Asymptomatic	1 [42].
	2. Severe patients' plasma	2. Severe > Non-severe & Healthy	2 [47].
	3. Hospitalized and discharged patients' serum	3. Hospitalized	3 [48].
	4. IMV-required patients' serum	4. IMV > Healthy	4 [49].
	5. Severe and ICU-admitted patients' serum	5. Severe > Mild	5 [50].
	6. Severe and mild patients' Serum	6. Severe > Mild	6 [51].
	7. ICU-admitted patients' plasma	7. ICU > Non- ICU	7 [52].
	8. Post-vaccine inflammatory syndrome	8. Case report	8 [53].
	9. Untreated-HIV and SARS-CoV-2 co-infection case plasma	9. Co-infection > Mono-infection	9 [30].

^aAn increasing trend in study groups is indicated by the '>' symbol.